Early Intervention in the Continuum of Hyperglycemia- The Role of Initial Combination Therapy


Thursday November 19, 2015, 
7:30 pm- 9:30 pm 

Hilton Universal City, Los Angeles 

555 Universal Hollywood Dr, Universal City, CA 91608

(818) 506-2500

View Faculty Here


Program Format

The program will intersperse panel discussions with didactic lectures,

leaving time for Q +A and Audience participation throughout  the activity


 Program Description

In the past, a major challenge in safely treating type 2 diabetes was in controlling glucose without inducing hypoglycemia and weight gain. Additionally many patients were largely unmonitored due to the antiquated approach of introducing new therapies only after failure. In recent years new agents were developed. The incretin based therapy, namely GLP1-RA and DPP4i, help improve insulin secretion and reduce endogenous glucose production; and SGLT2 ingibitors, which reduce glucose reabsorption, have been approved for the management of type 2 diabetes. The development of appropriate and safe therapeutic pathways led to new approaches in reaching and maintaining glycemic control. Early intervention in the continuum of hyperglycemia, often in combination, has the potential to slow the progression of diabetes and lead to clinician in developing treatment modalities which do not chase failure but rather reach success by implementing early intervention in combination achieving goals safely, while also impacting CV risk factors like blood pressure and weight and reduce complications.

—————————————————————————————

Symposium Agenda

miniagenda

—————————————————————————————

Learning Objectives:

Describe diabetes as a continuum of hyperglycemia with its progressive and accumulated complications. Explain how early and intensive intervention may halt, if not reverse, progression to complications, Discuss the contemporary approach to managing Diabetes addressing all risk factors, Analyze early intervention strategies with combination medications to achieve fast control to reduce complications, Describe the benefit of novel therapy specifically incretins and SLGT2 inhibitors and the potential effect beyond glycemia on weight, blood pressure, and the kidney.

Accreditation Information:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the accreditation council for Continuing Medical Education through the joint providership of PESI, Inc and Metabolic Endocrine Education Foundation (MEEF). PESI, Inc is accredited by the ACCME to provide continuing medical education for physicians. The PESI, Inc designated this live educational activity for a maximum of 2.0 AM PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: info@wcir.org or (818)342-1889